Use of oncolytic viruses for the eradication of drug-resistant cancer cells
- 29 July 2008
- journal article
- Published by The Royal Society in Journal of The Royal Society Interface
- Vol. 6 (31) , 179-186
Abstract
Targeted therapy using small-molecule inhibitors is a promising new therapy approach against cancer, but drug-resistant mutants present an obstacle to success. Oncolytic virus therapy, where viruses replicate specifically in cancer cells and kill them, is another promising therapy approach against cancer. While encouraging results have been observed in clinical trials, consistent success has not been possible so far. Based on a computational framework, I report that even if oncolytic virus therapy fails to eradicate a cancer, it can have the potential to eradicate the sub-population of drug-resistant cancer cells. Once this has occurred, targeted drug therapy can be used to induce cancer remission. For this to work, a drug resistance mutation must confer a certain fitness cost to the cell, as has been documented in the literature. The reason for this finding is that in the presence of a shared virus, the faster growing (drug-sensitive) cell population produces an amount of virus that is too much for the slower growing (drug-resistant) cell population to survive. This is derived from a population dynamic principle known as apparent competition. Therefore, a sequential combination of oncolytic virus and targeted therapies can overcome major weaknesses of either approach alone.Keywords
This publication has 56 references indexed in Scilit:
- History of Oncolytic Viruses: Genesis to Genetic EngineeringMolecular Therapy, 2007
- Model-driven approaches for in vitro combination therapy using ONYX-015 replicating oncolytic adenovirusJournal of Theoretical Biology, 2007
- Drug resistance in cancer: Principles of emergence and preventionProceedings of the National Academy of Sciences, 2005
- Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistanceProceedings of the National Academy of Sciences, 2005
- Gene Therapy for Killing p53-Negative Cancer Cells: Use of Replicating Versus Nonreplicating AgentsHuman Gene Therapy, 2003
- Chronic Myeloid LeukemiaHematology-American Society Hematology Education Program, 2003
- STI-571 must select for drug-resistant cells but ‘no cell breathes fire out of its nostrils like a dragon’Leukemia, 2002
- Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or AmplificationScience, 2001
- Chronic Myeloid LeukemiaNew England Journal of Medicine, 1999
- Regulation and Stability of Host-Parasite Population Interactions: I. Regulatory ProcessesJournal of Animal Ecology, 1978